Efficacy and safety of neoadjuvant targeted therapy in non-small cell lung cancer: a systematic review and meta-analysis - PubMed
3 hours ago
- #Neoadjuvant therapy
- #Non-small cell lung cancer
- #EGFR-TKI
- Neoadjuvant EGFR-TKI monotherapy shows promising efficacy and safety in EGFR-mutant NSCLC.
- Pooled objective response rate (ORR) was 61%, with grade ≥3 adverse events at 11%.
- Major pathological response (MPR) rate was 21%, and pathologic complete response (pCR) rate was 11%.
- Complete (R0) resection rate was high at 90%.
- ORR was higher in patients aged ≥60 years (69%) compared to <60 years (54%).
- pCR was higher in Chinese patients (10%) compared to non-Chinese patients (3%).
- Evidence is limited by the predominance of single-arm studies; large randomized trials are needed.